Loading…
← CockpitCompetitor Analysis › VERA Vera Therapeutics, Inc. Class AOpen in the cockpit ↗

Vera Therapeutics, Inc. Class AVERACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops therapies for autoimmune kidney diseases, led by atacicept for IgA nephropathy.

Momentum weak 25
Mkt cap
$1.85B
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$43.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.2%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$25.58
1D-2.4%
1W-16.1%
1M-14.9%
3M-18.2%
6M-26.1%
YTD-49.5%
1Y-13.2%
ATR %6.2%
Beta1.27
52w lowhigh54.4% off high

What Vera Therapeutics does

Develops therapies for autoimmune kidney diseases, led by atacicept for IgA nephropathy.

Has no approved product and earns no sales; spending on late-stage trials and launch preparation is funded by money raised from investors. Its lead drug, atacicept, was licensed from Merck KGaA, which would be owed milestone and royalty payments if it reaches the market.

Products and services

  • Atacicept (IgA nephropathy)
  • Pipeline in other autoimmune kidney diseases

Customers

  • Nephrologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Autoimmune kidney disease therapeutics

What could go right

  • IgA nephropathy launch potential
  • Broader autoimmune kidney disease pipeline

What could go wrong

  • Competitive IgA nephropathy landscape
  • Regulatory and approval timeline risk

Moat: none (IP / patents). Differentiated dual-pathway BAFF/APRIL mechanism but a competitive, fast-evolving IgA nephropathy field.

Headquarters: Brisbane, California, US · Founded: 2016 · Employees: 249

Named competitors

Vera Therapeutics at a glance

Size Vera Therapeutics (VERA) is a United States Health Care company (Biotechnology) with a market value of $1.85B, the 1820th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.58 on 18 Nov 2026.

Performance Over six months the shares fell 26.1%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth The operating margin is -4,160.1% (peer median -8.7%).

Valuation It trades at 149.9× enterprise value to sales against a peer median of 10.9× (most expensive of 15).

Short interest Short interest is 16.8% of the free float (30 Oct 2026).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 93VERA 74
Six months, rebased to 100: Vera Therapeutics against the median of its 20 peers (local-currency closes).

Vera Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$10.3M$0$0$0$0
Revenue growth—————
Gross profit$5.82M-$468,000-$2.17M$1.86M$846,000
EBITDA-$426M-$315M-$165M-$104M-$91.7M
Net income-$415M-$300M-$152M-$96.0M-$89.1M
Free cash flow-$376M-$242M-$136M-$92.2M-$67.7M
Capital expenditure$798,000$630,000$972,000$63,000$62,000
Total debt$75.4M$77.3M$54.6M$53.7M$31.3M

Quarterly statements and history in the cockpit →

Vera Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%300601COAGTRAXSEPNREPLBCRX688520ZBIOMRVITRVIRXRXSTOKVERA6-month return →1-month return →
Up and to the right = strong over both horizons. Vera Therapeutics is the large dot.

Vera Therapeutics competitors and peer comparison

Head to head with its named competitors (VERA vs NOVN.SW vs TVTX vs CALT.MI)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Vera Therapeutics VERA$1.85B-26%n/a-4,160%149.9×n/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Travere Therapeutics TVTX$4.82B+16%+49%-3%7.6×17.3%
Caltagirone CALT.MI$1.23B+4%+10%10%1.1×1.1%
Otsuka Hldgs 4578.T$39.9B+9%+11%18%2.3×1.6%
Vertex Pharmaceuticals VRTX$136B+25%+11%35%10.5×6.2%

How Vera Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vera Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureVERAPeer medianRank in peer set
1-month return-14.9%-1.6%5th lowest of 20
6-month return-26.1%-4.7%4th lowest of 19
Distance from 52-week high-54.4%-33.4%3rd lowest of 21
Operating margin-4,160.1%-8.7%lowest of 15
EV / Sales149.9×10.9×most expensive of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%4.2×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%

Questions

Who are Vera Therapeutics's main competitors?
Named competitors: Novartis (Fabhalta) (NOVN.SW), Travere Therapeutics (TVTX), Calliditas Therapeutics (CALT.MI), Otsuka Holdings (4578.T), Vertex Pharmaceuticals (VRTX). The cockpit's measured peer set (industry) also includes Shenzhen Kangtai Biological Products (300601.SZ), Hemab Therapeutics (COAG), First Tracks Biotherapeutics (TRAX), Septerna (SEPN), Replimune (REPL), BioCryst Pharmaceuticals (BCRX).
Is Vera Therapeutics expensive compared with its peers?
On ev / sales it trades at 149.9× against a peer median of 10.9×, most expensive of 15 in its peer set.
How has Vera Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -26.1% against -4.7% for the median peer; over one year -13.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.